Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 172 participants.

Also called NCT06759922

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 172 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06759922
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Pakistan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06759922. Randomized; no masking; primary purpose treatment. Start 2025-01-01 (actual); primary completion 2025-03-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Tab Metformin + Tab Glimepiride
Intervention (Drug)
Tab Metformin + Tab Empagliflozin
Intervention (Drug)
Tab Metformin +Tab Sitagliptin
Intervention (Drug)
Tab Metformin + Tab Empagliflozin + Tab Sitagliptin
Lead sponsor
Bahria University (class: other)

Record details

Record id
cardio:ct-nct06759922
Content hash
3089cf8effbeeaad7b020798326d3ef972ebabd3cde7c9811fa0be5837062ed2